Characterization of protein therapeutics by mass spectrometry: recent developments and future directions

[Orbitrap_SciLib]

Chen G, Warrack BM, Goodenough AK, Wei H, Wang-Iverson DB, Tymiak AA.
Drug Discov Today. 2011 Jan;16(1-2):58-64.
Mass spectrometry (MS) has become a powerful technology in the discovery and development of protein therapeutics in the biopharmaceutical industry. This review article describes recent developments and future trends in the characterization of protein therapeutics using MS. We discuss top-down MS for the characterization of protein modifications, hydrogen/deuterium exchange MS and ion mobility MS methods for higher order protein structure studies. Quantitative analysis of protein therapeutics (in vivo) by MS as an orthogonal approach to immunoassay for pharmacokinetics studies will also be illustrated.

http://www.sciencedirect.com/science/article/pii/S1359644610008068
Bioanalytical and Discovery Analytical Sciences, Research and Development, Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543, USA.